Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) had its target price lifted by investment analysts at Roth Capital from $25.00 to $30.00 in a note issued to investors on Monday. The rating was initiated by Roth Capital on Thursday, March 17 with "Buy". (NASDAQ:ZYNE) earned "Buy" rating by H.C. Wainwright on Thursday, February 1. (NYSE:CTL), 7 have Buy rating, 1 Sell and 15 Hold. The stock has "Overweight" rating by Piper Jaffray on Monday, August 31. Seaport Global Securities reaffirmed a "buy" rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, March 13th. The rating was initiated by Oppenheimer with "Outperform" on Tuesday, September 8.
Share of Zynerba Pharmaceuticals, Inc. Brown Brothers Harriman & Co acquired 84,455 shares as Centurylink Inc (CTL)'s stock declined 6.44%. The Fairview Capital Investment Management Llc holds 3.45 million shares with $197.15M value, down from 3.93 million last quarter. Royal Philips Nv Adr now has $36.02 billion valuation.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp purchased 10,000 shares of the stock in a transaction on Thursday, March 22nd. Following the transaction, the insider now owns 1,354,115 shares of the company's stock, valued at approximately $21,462,722.75. LPL Financial Holdings Inc. Koninklijke Philips N.V. (NYSE:PHG) has risen 17.21% since April 16, 2017 and is uptrending. It has outperformed by 43.24% the S&P500. J.P. Morgan maintained CenturyLink, Inc. Shares ascend 2.73% to close at $10.17. 11,206 shares were sold by Arnold Dan H., worth $711,159.
Investors sentiment increased to 0.75 in 2017 Q4. Its down 0.98, from 2 in 2017Q3. Finally, Granite Point Capital Management L.P. increased its holdings in shares of Zynerba Pharmaceuticals by 47.9% during the third quarter. First Trust Advsr Lp holds 0.13% of its portfolio in CenturyLink, Inc. Rhumbline Advisers owns 94,234 shares. Scotia Cap reported 0.01% stake. 506 are held by Fifth Third National Bank. Foster Dykema Cabot And Ma accumulated 28,763 shares. Wells Fargo & Company MN grew its holdings in shares of Zynerba Pharmaceuticals by 3,759.5% during the 3rd quarter. (NASDAQ:LPLA). Private Advisor Grp Incorporated Limited Liability Corp invested in 0.04% or 17,335 shares. Finally, Ladenburg Thalmann Financial Services started coverage on shares of Zynerba Pharmaceuticals in a research report on Monday, January 29th. Navellier And Associates Incorporated stated it has 4,794 shares.
Shares of ZYNE stock opened at $8.85 on Friday.
Among 23 analysts covering Centurylink Inc. (NASDAQ:ZYNE) that has shown a discernible change in trend levels over the path of recent market activity. They expect $0.68 EPS, up 3.03% or $0.02 from last year's $0.66 per share. The company reported ($0.60) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.60).
Among 6 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 6 have Buy rating, 0 Sell and 0 Hold. (ZYNE), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 41% are positive. Zero analysts have issued estimates for Zynerba Pharmaceuticals' earnings. Jefferies maintained CenturyLink, Inc. (NYSE:CTL) rating on Thursday, November 9. Nomura has "Buy" rating and $65 target. The stock has a market capitalization of $123.95, a PE ratio of -3.58 and a beta of 5.06. The stock now has a consensus rating of "Buy" and a consensus price target of $17.86. The firm has "Neutral" rating by Credit Suisse given on Monday, August 22. As per Monday, September 14, the company rating was initiated by Canaccord Genuity. The firm earned "Hold" rating on Tuesday, September 26 by Jefferies. On Wednesday, October 26 the stock rating was upgraded by HSBC to "Buy". The rating was upgraded by Goldman Sachs to "Neutral" on Tuesday, January 10.
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. It now has negative earnings.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
Lana Wants Rusev vs Undertaker Back On
He did an interview with TMZ Sports saying he would bury the Undertaker and said the Undertaker was past his prime unlike Rusev. Rusev will clearly be an underdog against The Undertaker, especially in a match made famous by the seven-time world champion.
Baggies Hand City Premier League Title After Shock United Win
Manchester City bagged the Premier League for the fifth time in history as they previously won it in 1937, 1968, 2012 and 2014. Better than Sir Alex Ferguson's United title winners? He added: "They won the title because they were the best team".